Financial Performance - Operating revenue rose by 14.42% to CNY 2.31 billion year-on-year[10] - Net profit attributable to shareholders increased by 1.47% to CNY 75.59 million[10] - The company’s basic and diluted earnings per share remained stable at CNY 0.09[10] - Total operating revenue for the current period reached ¥2,307,023,332.38, an increase of 14.4% compared to ¥2,016,331,033.53 in the previous period[36] - Net profit for the current period was ¥140,948,205.36, representing a 19.7% increase from ¥117,618,203.06 in the previous period[36] - The net profit attributable to the parent company was ¥75,587,178.66, slightly up from ¥74,489,880.25, indicating a growth of 1.5%[36] Assets and Liabilities - Total assets increased by 4.43% to CNY 14.59 billion compared to the end of the previous year[10] - Total liabilities rose to ¥8,493,830,354.55, compared to ¥8,013,892,377.92, marking an increase of 6.0%[28] - Current liabilities totaled ¥5,321,940,001.17, an increase of 4.6% from ¥5,085,912,030.19[28] - Non-current liabilities increased to ¥3,171,890,353.38 from ¥2,927,980,347.73, representing an 8.3% growth[28] - Owner's equity totaled ¥6,097,788,243.29, up from ¥5,958,194,233.01, indicating a growth of 2.3%[28] Cash Flow - Net cash flow from operating activities improved significantly, reaching CNY 37.71 million, compared to a negative CNY 64.82 million in the same period last year[10] - Cash flow from operating activities generated a net amount of ¥37,710,750.39, a significant recovery from a negative cash flow of -¥64,816,355.54 in the previous period[41] - Cash inflow from financing activities was $624.90 million, an increase of 30.2% from $480.00 million in the previous period[45] - Net cash flow from financing activities was $116.96 million, down 38.8% from $191.30 million in the prior period[45] Shareholder Information - The number of shareholders totaled 34,109, with the largest shareholder, Zhejiang Haizheng Group Co., Ltd., holding 38.20% of shares[13] Government Subsidies - The company received government subsidies totaling CNY 90 million for strategic projects, with CNY 29 million received in the current reporting period[14] - The company’s other income increased by 142.93% to CNY 15.20 million, mainly due to increased government subsidies[14] Investments and Acquisitions - The company and its subsidiary, Haizheng Pfizer Pharmaceutical Co., Ltd., have agreed to invest up to RMB 410 million in purchasing office space in Shanghai, with prepayments totaling RMB 21.87 million and RMB 60.91 million respectively[18] - The company has terminated its application for issuing convertible bonds and non-public stock issuance, with the relevant matters approved by the Zhejiang State-owned Assets Supervision and Administration Commission[19] - The company’s subsidiary, Haizheng Pharmaceutical (Hangzhou) Co., Ltd., has contributed fixed assets and land use rights valued at RMB 739.03 million to Haizheng Pfizer, with RMB 333.62 million already contributed as of the reporting period[20] Current Assets - As of the end of the reporting period, the company's total current assets amounted to RMB 5.82 billion, an increase from RMB 5.65 billion at the beginning of the year[26] - Cash and cash equivalents at the end of the reporting period were RMB 2.30 billion, up from RMB 2.22 billion at the beginning of the year[26] - Accounts receivable increased to RMB 1.37 billion from RMB 1.13 billion, indicating a growth of approximately 22%[26] - Inventory decreased slightly to RMB 1.52 billion from RMB 1.54 billion, reflecting a reduction of about 1%[26] Other Financial Metrics - The weighted average return on equity decreased by 0.042 percentage points to 1.535%[10] - Total operating costs amounted to ¥2,127,054,335.40, up from ¥1,855,171,296.05, reflecting a growth of 14.6%[36] - Cash outflow from investing activities totaled $135.06 million, compared to $148.76 million in the prior period, resulting in a net cash flow from investing activities of -$119.06 million[45] - Total cash outflow for employee compensation was $131.04 million, up 26.5% from $103.57 million[45] - Total cash paid for taxes was $50.27 million, significantly higher than $13.82 million in the previous period[45]

Financial Performance - The net profit for the parent company in 2013 was CNY 98,219,730.63, with a statutory surplus reserve of CNY 9,821,973.06 being allocated [4]. - The total distributable profit for shareholders in 2013 amounted to CNY 1,386,094,971.15 after deducting cash dividends of CNY 92,367,996.38 [4]. - A cash dividend of CNY 1.1 per 10 shares (including tax) is proposed, totaling CNY 92,367,996.38 for distribution [4]. - In 2013, the company achieved operating revenue of CNY 8.60 billion, a year-on-year increase of 48.31% compared to CNY 5.80 billion in 2012 [28]. - The net profit attributable to shareholders was CNY 301.86 million, a slight increase of 0.19% from CNY 301.29 million in 2012 [28]. - The total profit for the year was CNY 662 million, a significant increase of 100.44% compared to the previous year [35]. - The company reported a basic earnings per share of CNY 0.36, unchanged from 2012 [29]. - The weighted average return on equity was 6.31%, a decrease of 0.27 percentage points from 2012 [29]. - The company reported a net loss from investment activities of CNY 1,928,640,174.36, which is a 15.83% increase in losses compared to the previous year [59]. - The company’s financial expenses increased by 137.71% to CNY 139,202,344.23, primarily due to increased bank borrowings to expand production [60]. Operational Highlights - The company operates in the pharmaceutical sector, focusing on chemical raw materials, intermediates, and various forms of drug production and sales [20]. - The company has expanded its business scope to include veterinary medicine since January 2007 [20]. - The audit report for 2013 was issued by Tianjian Accounting Firm with a standard unqualified opinion [4]. - The company achieved a revenue of CNY 8.60 billion, a 48.31% increase compared to the previous year, primarily driven by the contribution from its subsidiary, Haizheng Pfizer Pharmaceutical [45]. - Sales revenue reached CNY 4.32 billion, with Haizheng's formulation products growing by 38% and net profit at CNY 445 million [40]. - The company reported a significant increase in sales expenses, which rose by 232.55% to CNY 1.25 billion, reflecting the growing scale of its formulation business [43]. - The company has a dedicated R&D team of 669 personnel, with 34% holding advanced degrees [76]. - The company has focused on new product development and technological innovation, enhancing its competitive edge in the pharmaceutical market [72]. Research and Development - The company aims to enhance its R&D capabilities to transition from raw materials to formulations and from generic drugs to innovative drugs [35]. - The company increased R&D investment to CNY 397 million, accounting for 4.61% of total revenue, ensuring sustainable long-term growth through a rich product pipeline [36]. - The company submitted 28 domestic registration applications and approved 5 for production, along with 2 for clinical trials, demonstrating strong regulatory progress [36]. - The company applied for 39 patents, including 17 PCT applications, highlighting its commitment to innovation and intellectual property development [36]. - The company is developing 8 new innovative drugs, with HS-25 approved in Singapore and entering Phase II clinical trials in the US [74]. Market and Sales - The gross profit margin for the company's products improved by nearly 9 percentage points compared to the previous year [35]. - The sales revenue from the company's formulations increased by 10 percentage points compared to the same period last year [35]. - Revenue from the oncology drugs segment was CNY 966,677,751.84, with a year-on-year growth of 31.97% [64]. - The sales revenue from anti-infection drugs increased by 5.87%, totaling CNY 511,054,184.55 [63]. - Domestic market revenue accounted for CNY 7,704,337,655.39, reflecting a growth of 55.14% [66]. Corporate Governance - The company emphasizes the importance of risk awareness regarding forward-looking statements in its reports [5]. - The company has established a sustainable product reserve system in the biopharmaceutical sector [73]. - The company is actively seeking international cooperation to enhance its formulation export strategy, moving away from traditional processing models [74]. - The company has a diverse board with members having extensive experience in various sectors, including pharmaceuticals and finance [170]. - The company emphasizes the importance of independent directors in its governance structure, enhancing oversight and strategic direction [172]. Environmental and Compliance - The company’s environmental management system has been certified with ISO14001 since 2001, and it has established an EHS management system since 2005 [114]. - The company adheres to the GB8978-1996 wastewater discharge standards, ensuring all wastewater is treated to meet standards before discharge [115]. - The company’s waste gas emissions comply with GB16297-1996 standards, utilizing advanced treatment processes to control odor emissions [115]. - The company has implemented strict measures for hazardous waste management, ensuring proper disposal and treatment [116]. Shareholder Information - The total number of shareholders at the end of the reporting period was 27,724, with the top shareholder, Zhejiang Haizheng Group Co., Ltd., holding 38.20% of shares [154]. - Zhejiang Haizheng Group Co., Ltd. holds 320,783,590 shares, representing a significant portion of the company's equity [155]. - The company revised its profit distribution policy to protect minority shareholders' interests, ensuring clarity in cash dividend standards and procedures [111]. - The company reported a net profit for the reporting period, with undistributed profits being positive, but no cash dividend distribution plan was proposed [112]. Employee and Management - The total number of employees in the parent company is 3,988, while the main subsidiaries have 4,440 employees, resulting in a total of 8,428 employees [183]. - The professional composition includes 2,984 production personnel, 2,109 sales personnel, 2,568 technical personnel, 132 financial personnel, and 635 administrative personnel [183]. - The company implements an incentive-based comprehensive compensation system, focusing on position, ability, and performance [184]. - The total remuneration for all directors, supervisors, and senior management in the reporting period amounted to 14.89795 million yuan [180].